LONDON, July 29, 2015 /PRNewswire/ --
Commenting on GSK's Q2 performance, the first since the Novartis transaction closed, CFO Simon Dingemans reveals sales rose during the period and that newly acquired businesses are performing in line with expectations. Ahead of a November R&D update day he reiterates the company's commitment to sustainable innovation.
The interview and transcript are available now on http://video.merchantcantos.com
MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email email@example.com or phone +44-(0)207-936-1352.